New U.S. Patent Allowance Granted to AXIM® Biotechnologies, Inc. for Cannabinoid Ophthalmic Solutions for Glaucoma and Conjunctivitis Treatment

NEW YORK, Oct. 05, 2017, AXIM, (GLOBE NEWSWIRE)  AXIM® Biotechnologies, Inc. (AXIM® Biotech), (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/982,610, a patent that claims the use of an ophthalmic solution comprising cannabinoids for the treatment of glaucoma and symptomatic relief of conjunctival inflammation. A Notice of Allowance is issued after the USPTO makes a determination that a
http://bit.ly/2fNXM53